R&D712 LAI 6M

R&D712 LAI 6M is a long-acting injectable (LAI) formulation being developed by Bostal Pharma for the treatment of schizophrenia and bipolar I disorder. Developed via the 505(b)(2) regulatory pathway, the drug is designed to provide therapeutic coverage for a duration of six months per dose. As a 505(b)(2) candidate, it is a reformulation of an existing active pharmaceutical ingredient, likely a second-generation antipsychotic, optimized for extended release to improve patient compliance and maintain stable plasma concentrations. The drug is currently in early-stage development, with clinical milestones projected through 2030.